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Conclusion: Although radiotherapy for painful bone 
metastases leads to a meaningful pain response, QoL does 
not improve after treatment. Initially, it remains stable 
followed by deterioration towards the end of life. 
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Purpose or Objective: The incidence of p16-overexpression 
and the role of human papillomavirus (HPV) in cutaneous 
head and neck squamous cell carcinoma (cHNSCC) is unclear. 
In the unknown primary setting, where cHNSCC is a potential 
putative site, p16 status is being used to guide management 
despite varying reports of its incidence in non-oropharyngeal 
sites.  
 
Material and Methods: 143 patients with cHNSCC lymph node 
metastases involving the parotid gland were evaluated for 
p16 expression by immunohistochemistry. Detection of 18 
high-risk HPV subtypes was performed using HPV RNA in situ 
hybridization on a subset of 59 patients. Results were 
correlated with clinicopathological features and outcomes 
 
Results: Median follow up time was 5.3 years. No differences 
were observed in clinicopathological factors based on p16 
status. p16 was positive, intermediate and negative in 45 
(31%), 21 (15%) and 77 (54%) of cases, respectively. No high-
risk HPV subtypes were identified, irrespective of p16 status. 
p16 status was not prognostic for overall (HR 1.08 95% CI 
[0.85 - 1.36], p=0.528), cancer-specific (HR 1.12 95% CI [0.77 
- 1.64], p=0.542) or progression-free survival (HR 1.03 95% CI 
[0.83 - 1.29], p=0.783). Distant metastasis free survival, 
freedom from locoregional failure and freedom from local 
failure were also not significantly associated with p16 status. 
 
Conclusion: p16 positivity is common but not prognostic in 
cHNSCC lymph node metastases. High-risk HPV subtypes are 
not associated with p16-positivity, and do not appear to play 
a role in this disease. HPV testing, in addition to p16-status in 
the unknown primary setting may provide additional 
information in determining a putative primary site. 
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Purpose or Objective: To investigate the prognostic 
significance of tumore-related leukocytosis (TRL) in cervical 
cancer patients treated with definitive radiotherapy 
 
Material and Methods: Between 1986 and 2012, 2,456 
patients with uterine cervical cancer (FIGO stage IA-IB 494, 
stage IIA-IIB 1530, stage IIIA-IIIB 394 and stage IVA 38) who 
received definitive radiotherapy (62.6%) or platinum-based 
chemoradiotherapy (37.4%) consisting of EBRT and ICBT were 
retrospectively analyzed. TRL was defined as WBC count of 
≥9,000/μL on ≥2 occasions at the time of diagnosis and during 
the course of treatment. The neutrophil/lymphocyte ratio 
(NLR) was defined as the absolute neutrophil count divided 
by the absolute lymphocyte count. Locoregional failure free 
survival (LRFFS) and overall survival (OS) were compared 
between patients with or without TRL. 
 
Results: Median age of all patients was 55 years (range, 21-
87) and the median follow-up time was 65.1 months (range, 
0.7-347.8). Among 2,456 patients included in this study, TRL 
was observed in 398 (16%) at the initial diagnosis. Patients in 
TRL(+) group were younger in age and had larger tumor, 
advanced FIGO stage and more common LN metastases (all p 
< 0.05). TRL (+) group showed relatively lower rate of 
complete remission (CR) (90% vs. 97%, p = 0.042).The 10-year 
LRFFS and OS for all patients were 84% and 78%, respectively. 
Compared to TRL(-) group, LRFFS and OS were significantly 
lower in TRL(+) group (10-yr LRFFS: 69% vs. 87%, p <0.001; 
10-yr OS: 63% vs. 81% p < 0.001). After propensity score 
matching by age, FIGO stage, tumor size, LN metastasis, 
histologic subtype and pretreatment hemoglobin (Pre Tx Hb), 
both groups were well matched. The LR control and OS rate 
of TRL (+) group was still significantly lower than those of 
TRL (-) group. In multivariate analysis, advanced FIGO stage, 
non-SqCCa, larger tumor size and TRL were identified as risk 
factors for LRFFS and OS (all p < 0.05). In addition, Pre Tx 
Hb, LN metastasis and high NLR (≥2.5) were also associated 
with poorer OS (all p < 0.05). Among patients with LRF 
(n=345), patients with TRL at the time of recurrence 
accounted for 26% and showed relatively poorer median OS (6 
vs. 12 months, p = 0.001). 
 
Conclusion: This study supports the aggressive nature and 
poor radiation response of cervical cancer with leukocytosis. 
Given the unfavorable features and higher probability of 
treatment failure, optimal therapeutic approach and careful 
monitoring for early detection of recurrence should be 
considered for these patients. 
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Purpose or Objective: Stage II testicular seminoma is highly 
curable with radiotherapy (RT) or multiagent chemotherapy 
(MACT). These modalities have not been prospectively 
compared. Due to the rarity of stage II seminoma, prior 
studies are limited by small sample size.  NCCN guidelines 
recommend RT as the preferred treatment for stage IIA, 
while EUA guidelines equally allow for RT or MACT.  Both 
guidelines are equivocal for stage IIB, and recommend MACT 
for stage IIC. 
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Material and Methods: Using the National Cancer Data Base, 
we identified stage II seminoma patients treated with 
orchiectomy and either RT or MACT diagnosed from 1998-
2012.  Separately for stage IIA and IIB, factors affecting 
treatment modality (RT vs. MACT) were studied using a 
parsimonious multivariable logistic regression model.  
Propensity scores for treatment decision were incorporated 
into a multivariable Cox regression analysis of overall 
survival. 
 
Results: Analysis included 2,437 patients (IIA=960, IIB=812, 
IIC=665).  Median follow-up was 65 months (IQ range 34-
106).  Rates of RT utilization by stage were: IIA=78.1%, 
IIB=54.4%, IIC=4.2%.  Rates of MACT utilization by stage were: 
IIA=21.9%, IIB=45.6%, IIC=95.8%.  Median RT dose was: 
IIA=30.9 Gy (IQR 25.5-35.5) and IIB=35.5 Gy (IQR 31.1-36.0).  
For both IIA and IIB patients, later year of diagnosis, 
treatment at an academic facility, and pathologic assessment 
of lymph node(s) were associated with increased use of MACT 
vs. RT.  Also predictive for preferential use of MACT were 
Charlson-Deyo comorbidity score of 1+ and non-private 
insurance for IIA patients, and T stage of 2+ for IIB patients. 
Unadjusted 5-year survival by stage was: IIA=97.1% (95% 
confidence interval [CI] 96.1-98.1), IIB=93.9% (95% CI 92.1-
95.7), IIC=92.6% (95% CI 90.6-94.6), log-rank p=0.006.  
Factors predicative of improved survival on multivariable 
analysis included age<40, private insurance, and comorbidity 
score of zero.  For IIA patients, overall survival was improved 
with RT compared to MACT with a 5-year survival of 99.0% 
(95% CI 98.2-99.8) vs. 93.0% (95% CI 89.0-97.0).  This 
advantage persisted on multivariable analysis with a HR of 
0.22 (95% CI 0.08-0.64, p=0.005) and propensity adjusted HR 
of 0.28 (95% CI 0.09-0.86, p=0.027).  For IIB patients, 5-year 
survival was 95.2% (95% CI 92.8-97.6) for RT and 92.4% (95% 
CI 89.2-95.6) for MACT (log-rank p= 0.041).  This was not 
statistically significant on multivariable analysis with a HR of 
0.74 (95% CI 0.32-1.70, p=0.475) and propensity adjusted HR 
of 0.77 (95% CI 0.33-1.80, p=0.549).  An unadjusted Kaplan-
Meier plot by stage and treatment is given in Figure 1. 
 
 
 
 
Conclusion: In the largest cohort of stage II seminoma 
patients evaluated to date, we have identified numerous 
factors predictive for treatment selection and overall 
survival.  We have shown a survival advantage for stage IIA 
patients treated with RT compared with MACT, while no such 
survival advantage was seen for stage IIB patients. 
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Purpose or Objective: In 2009 we reported promising first 
results of a European pooled analysis which evaluated the use 
of intraoperative radiation therapy (IORT) in the treatment of 
soft tissue sarcomas. However, comparison of these results 
with non-IORT series seemed difficult, mainly because of the 
inclusion of grossly incomplete resected lesions, patients 
treated without additional external beam radiation therapy 
(EBRT) and comparatively short follow-up. Therefore we re-
analyzed our data limited to the patients who received IOERT 
preceeded or followed by EBRT after gross total resection 
with extended follow-up.  
 
Material and Methods: Three European expert centers 
participated in the current analysis. Patients with gross 
incomplete resection, missing documentation of EBRT or 
primary lesions outside the extremities were excluded, 
leaving 259 patients for analysis. Median age was 55 years 
and median tumor size 8 cm. 80% of the patients presented in 
primary situation with 81% of the tumors located in the lower 
limb. Stage at presentation was I:9%, II:47%, III:39%, IV:5%. 
Most patients showed high grade lesions (FNCLCC grade 1:9%, 
2:34%, 3:58%, predominantly liposarcoma (31%) and MFH 
(27%). IOERT was applied to the tumor bed with a median 
dose of 12 Gy using a median electron energy of 8 MeV. 
IOERT was preceeded (17%) or followed (83%) by EBRT with a 
median dose of 45 Gy in all patients. 37% of the patients 
received additional chemotherapy.  
 
Results: Median follow up was 63 months. Surgery resulted in 
free margins (R0) in 71% while 29% suffered from microscopic 
positive margins (R1). We observed 27 local failures, 
transferring into a 5-year local control rate of 86%. Univariate 
analysis revealed primary vs recurrent situation and resection 
margin as significant factors for local control but only 
resection margin (5-year LC rate 94% vs 70%, HR 3.8) 
remained significant in multivariate analysis. Distant failure 
was found in 70 patients, resulting in a 5-year distant control 
rate of 69%. Factors with significant impact on distant control 
in univariate analysis were histology, grading, resection 
margin and stage IV prior/at IOERT, but only grading and 
stage IV remained significant in multivariate analysis. 
Actuarial 5-year rates of FFTF and OS were 61% and 78%, 
respectively. Significant factors for overall survival were only 
grading and stage IV prior/at IOERT (uni- and multivariate). 
Secondary amputations were needed in 14 patients (5%) 
resulting in a final limb-preservation rate of 95%. Good 
functional outcome was achieved in 81%.  
 
Conclusion: Combination of IOERT and EBRT after limb 
sparing surgery resulted in encouraging local control and 
overall survival with excellent rates of preserved limb 
function in this unfavourable patient group. Our analysis 
identified resection margin as most important factor for local 
control while overall survival was mainly influenced by 
grading and stage IV prior/at IOERT.  
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